|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0004238,
umls-concept:C0008976,
umls-concept:C0018801,
umls-concept:C0021149,
umls-concept:C0030705,
umls-concept:C0033105,
umls-concept:C0043031,
umls-concept:C0441471,
umls-concept:C0684224,
umls-concept:C0966370,
umls-concept:C1280500,
umls-concept:C1302234,
umls-concept:C1707455,
umls-concept:C2745888
|
|
pubmed:issue |
6-7
|
|
pubmed:dateCreated |
2007-5-14
|
|
pubmed:abstractText |
Patients with atrial fibrillation (AF) who also have heart failure have a worse outcome but the diagnosis of heart failure is often missed.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1388-9842
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
9
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
730-9
|
|
pubmed:dateRevised |
2011-6-8
|
|
pubmed:meshHeading |
pubmed-meshheading:17360232-Age Factors,
pubmed-meshheading:17360232-Aged,
pubmed-meshheading:17360232-Aged, 80 and over,
pubmed-meshheading:17360232-Anticoagulants,
pubmed-meshheading:17360232-Atrial Fibrillation,
pubmed-meshheading:17360232-Azetidines,
pubmed-meshheading:17360232-Benzylamines,
pubmed-meshheading:17360232-Drug Therapy, Combination,
pubmed-meshheading:17360232-Female,
pubmed-meshheading:17360232-Follow-Up Studies,
pubmed-meshheading:17360232-Heart Failure,
pubmed-meshheading:17360232-Humans,
pubmed-meshheading:17360232-Male,
pubmed-meshheading:17360232-Middle Aged,
pubmed-meshheading:17360232-Multicenter Studies as Topic,
pubmed-meshheading:17360232-Proportional Hazards Models,
pubmed-meshheading:17360232-Prospective Studies,
pubmed-meshheading:17360232-Randomized Controlled Trials as Topic,
pubmed-meshheading:17360232-Risk Factors,
pubmed-meshheading:17360232-Sodium Potassium Chloride Symporter Inhibitors,
pubmed-meshheading:17360232-Survival Rate,
pubmed-meshheading:17360232-Thromboembolism,
pubmed-meshheading:17360232-Warfarin
|
|
pubmed:articleTitle |
Prevalence of markers of heart failure in patients with atrial fibrillation and the effects of ximelagatran compared to warfarin on the incidence of morbid and fatal events: a report from the SPORTIF III and V trials.
|
|
pubmed:affiliation |
Department of Cardiology, Kingston-upon-Hull, UK. j.g.cleland@hull.ac.uk <j.g.cleland@hull.ac.uk>
|
|
pubmed:publicationType |
Journal Article,
Comparative Study
|
